Visszavonva2. fázis
Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).
A legfontosabb adatok
- Ki végzi
- Sun Yat-sen University
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 2. fázis
- Kezdés
- 2024. jún. 1.
- Várható befejezés
- 2029. ápr. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Aumolertinib
- A regiszteradat frissítve
- 2024. december 10.
- Miért állt le
- Slow accrual
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- Target population is high risk NSCLC with resection option for potential cure, as assessed by a faculty surgeon at SYSUCC. This may include clinical stage IB (≥4cm), II and IIIA. Subjects with N3 nodal involvement are not included
- Subjects should have a detected sensitizing EGFR
- Written informed consent provided
- Male and female, aged 18-75 years
- Able to comply with the required protocol and follow-up procedures, and able to receive oral medications
- Blood and specimens before and after treatment must be provided
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy ≥12 weeks
- EGFR activating mutation in exon 19 or 21
- Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level)
- Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases
- Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min
- Female subjects should not be pregnant or breast-feeding
Ki nem vehet részt
- Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab)
- A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study
- Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease)
- Known severe hypersensitivity to aumolertinib or any of the excipients of this product
- Evidence of clinically active interstitial lung disease
- Eye inflammation not fully controlled or conditions predisposing the subject to this
- A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease
- History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted
- Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over)
- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Ingredients mixed with small cell lung cancer patients
- History of neurologic or psychiatric disorders
- Inability to comply with protocol or study procedures
- Women who are pregnant or nursing
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI showing activity against EGFR-sensitizing mutations and EGFR T790M mutation. The third-generation EGFR-TKI osimertinib has been approved in the adjuvant setting. This study is to studying 3-year aumolertinib as adjuvant therapy to see how well it works in treating patients with resected stage IB-IIIA NSCLC harboring sensitizing EGFR mutations.
A vizsgálat csoportja
- AumolertinibA vizsgált kezelés
Aumolertinib 110 mg once daily (110 mg per day) orally for 36 months.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Single-Arm, Open-Lable Study of Adjuvant Aumolertinib for Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
- A regiszteradat frissítve
- 2024. december 10.